Mostrar el registro sencillo del ítem

dc.contributor.authorLucena-González, María Isabel 
dc.contributor.authorVillanueva-Paz, Marina
dc.contributor.authorAlvarez-Alvarez, Ismael
dc.contributor.authorAithal, Guruprasad P.
dc.contributor.authorBjornsson, Einar S.
dc.contributor.authorCakan-Akdogan, G.
dc.contributor.authorCubero, Francisco Javier
dc.contributor.authorEsteves, Freddy
dc.contributor.authorFalcón-Pérez, Juan Manuel
dc.contributor.authorFromenty, B.
dc.contributor.authorGarcia-Ruiz, C.
dc.contributor.authorGrove, J.I.
dc.contributor.authorKonu, O.
dc.contributor.authorKranendonk, M.
dc.contributor.authorKullak-Ublick, Gerd A
dc.contributor.authorMiranda, J.P.
dc.contributor.authorRemesal-Doblado, A.
dc.contributor.authorSancho-Bru, P.
dc.contributor.authorNelson, L.
dc.contributor.authorAndrade-Bellido, Raúl Jesús 
dc.contributor.authorFernandez-Checa, J.C.
dc.date.accessioned2024-01-26T11:50:34Z
dc.date.available2024-01-26T11:50:34Z
dc.date.issued2023-12-28
dc.identifier.citationM.I. Lucena, M. Villanueva-Paz, I. Alvarez-Alvarez, G.P. Aithal, E.S. Björnsson, G. Cakan-Akdogan, F.J. Cubero, F. Esteves, J.M. Falcon-Perez, B. Fromenty, C. Garcia-Ruiz, J.I. Grove, O. Konu, M. Kranendonk, G.A. Kullak-Ublick, J.P. Miranda, A. Remesal-Doblado, P. Sancho-Bru, L. Nelson, R.J. Andrade, A.K. Daly, J.C. Fernandez-Checa, Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet, Pharmacological Research, Volume 200, 2024, 107046, ISSN 1043-6618, https://doi.org/10.1016/j.phrs.2023.107046. (https://www.sciencedirect.com/science/article/pii/S1043661823004024)es_ES
dc.identifier.urihttps://hdl.handle.net/10630/29305
dc.description.abstractIn the current article the aims for a constructive way forward in Drug-Induced Liver Injury (DILI) are to highlight the most important priorities in research and clinical science, therefore supporting a more informed, focused, and better funded future for European DILI research. This Roadmap aims to identify key challenges, define a shared vision across all stakeholders for the opportunities to overcome these challenges and propose a high-quality research program to achieve progress on the prediction, prevention, diagnosis and management of this condition and impact on healthcare practice in the field of DILI. This will involve 1. Creation of a database encompassing optimised case report form for prospectively identified DILI cases with well-characterised controls with competing diagnoses, biological samples, and imaging data; 2. Establishing of preclinical models to improve the assessment and prediction of hepatotoxicity in humans to guide future drug safety testing; 3. Emphasis on implementation science and 4. Enhanced collaboration between drug-developers, clinicians and regulatory scientists. This proposed operational framework will advance DILI research and may bring together basic, applied, translational and clinical research in DILI.es_ES
dc.description.sponsorshipFunding for open access charge: Universidad de Malaga/CBUA. The present study has been supported by grants from Instituto de Salud Carlos III (ISCIII) (contract numbers: PID2022–140169OB-C21; PI21/01248; PI19/00883) and from Consejería de Salud de Andalucía (contract number: PEMP-0127–2020, Spain), cofounded by the European Union. This research was funded by HORIZON-HLTH-2022-STAYHLTH-02, grant number 101095679. Funded by the European Union. Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them. MK was partially supported by Grant UID/BIM/0009/2020 of the Portuguese Fundação para a Ciência e a Tecnologia (FCT). MVP and IAA hold Sara Borrell research contracts from ISCIII (CD21/00198 and CD20/00083, respectively). This research was supported by CIBERehd – Consorcio Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – European Regional Development Fund. JIG and GPA are supported by NIHR Nottingham Biomedical Research Centre [NIHR203310]. The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health. This publication is based upon work from COST Action “CA17112—Prospective European Drug-Induced Liver Injury Network” supported by COST (European Cooperation in Science and Technology); www.cost.eu.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectHígadoes_ES
dc.subjectAlergia a los medicamentoses_ES
dc.subjectInvestigaciónes_ES
dc.subject.otherIdiosyncratic drug-induced liver injuryes_ES
dc.subject.otherPreclinical modelses_ES
dc.subject.otherIntegrative databasees_ES
dc.subject.otherDILI predictiones_ES
dc.subject.otherHumanized mouse modelses_ES
dc.subject.otherOrgan-on-a-chipes_ES
dc.subject.otherDrug safetyes_ES
dc.subject.other3D culturees_ES
dc.subject.otherZebrafish modeles_ES
dc.subject.otherExtracellular vesicleses_ES
dc.subject.otherFamilial studieses_ES
dc.titleRoadmap to DILI research in Europe. A proposal from COST action ProEuroDILINetes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.centroFacultad de Medicinaes_ES
dc.identifier.doi10.1016/j.phrs.2023.107046
dc.rights.ccAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional